Clinical significance of serum SP-D as a biomarker for antifibrotics in idiopathic pulmonary fibrosis (IPF): Post hoc analysis of a phase 3 trial of pirfenidone in Japan

Chiba, Hirofumi; Ikeda, Kimiyuki; Azuma, Arata; Kondoh, Yasuhiro; Ogura, Takashi; Terada, Yoshio; Ebina, Masahito; Miyazawa, Shogo; Sakaguchi, Hiroki; Suga, Moritaka; Sugiyama, Yukihiko; Nukiwa, Toshihiro; Kudoh, Shoji; Takahashi, Hiroki

doi:10.1183/13993003.congress-2019.pa2249

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the INMARK trial, baseline levels of C-reactive protein degraded by matrix metalloproteinase (MMP)-1/8, collagen 3 degraded by MMP-9, C-reactive protein, Krebs von den Lungen 6 (KL-6) and surfactant protein D (SP-D) were predictive of disease progression, with nintedanib reducing collagen synthesis in the early phases of the treatment, as measured by N-terminal propeptide of type VI collagen and SP-D [12,13]. A phase III trial of pirfenidone in Japanese IPF patients revealed that a decrease in serum concentration of SP-D was predictive of a good response to the drug [14]. The INSTAGE trial showed a reduction of collagen 6 degraded by MMP-2/9 and citrullinated vimentin degraded by MMP-2/8 in patients treated with nintedanib plus sildenafil compared to nintedanib alone [15].…”

Section: Idiopathic Interstitial Pneumoniasmentioning

confidence: 99%

ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly

et al. 2020

View full text Add to dashboard Cite

This article discusses a selection of the scientific presentations in the field of interstitial lung diseases (ILDs) that took place at the 2019 European Respiratory Society International Congress in Madrid, Spain. There were sessions from all four groups within Assembly 12: group 12.01 “Idiopathic interstitial pneumonias”, group 12.02 “ILDs/diffuse parenchymal lung diseases (DPLDs) of known origin”, group 12.03 “Sarcoidosis and other granulomatous ILDs/DPLDs” and group 12.04 “Rare ILDs/DPLDs”. The presented studies brought cutting-edge developments on several aspects of these conditions, including pathogenesis, diagnosis and treatment. As many of the ILDs are individually rare, the sharing of experiences and new data that occur during the Congress are very important for physicians interested in ILDs and ILD patients alike.

show abstract